Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by 1DoxieDollaron Sep 29, 2022 10:06am
88 Views
Post# 34994616

RE:RE:BIOV CEO Interview

RE:RE:BIOV CEO InterviewShort term thinking is what got the world in the Covid mess in  the first place.  When the SARS1 pandemic waned in 2004, everyone said "gee, nothing more to worry about."   Remeber that SARS1 is a sarebecovirus, as is SARS-CoV2.   Walking away from developing a SARS1 vaccine due to lack of political and investor interest at the time (not having it spread in the US was a big factor too) set up the world to scramble for a solution to SARS2 using what was learned about SARS1. Maybe Covid is thankfully waning, but walking from what is sure to be a repeat with another sarbecovirus is short sighted.   
 
<< Previous
Bullboard Posts
Next >>